Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yousuf Sayeed

Interventional Pain Medicine Naperville, IL Medical Doctor

NPI 1932155926 CMS profile 86993

2940 Rollingridge Rd, Naperville, IL 60564

Open in the dashboard

General payments

$13,268

236 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yousuf Sayeed of Naperville, IL is reported in the CMS Open Payments database as having received $13,268 across 236 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,651 62
2024 General $1,360 37
2023 General $4,580 37
2022 General $884 19
2021 General $1,180 22
2020 General $854 23
2019 General $1,759 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yousuf Sayeed
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Yousuf Sayeed were reported at $2,651. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Yousuf Sayeed Interventional Pain Medicine median Middle half National median
2019 $1,759 $684 $216–$2,079 $163
2020 $854 $382 $122–$1,109 $114
2021 $1,180 $552 $167–$1,554 $132
2022 $884 $605 $187–$1,924 $149
2023 $4,580 $671 $195–$1,915 $160
2024 $1,360 $684 $206–$1,837 $164
2025 $2,651 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $3,721 18 payments
  2. Abbott Laboratories $2,387 44 payments
  3. Boston Scientific Corporation $1,190 36 payments
  4. Globus Medical, Inc. $994 12 payments
  5. Medtronic, Inc. $871 19 payments
  6. BIOTRONIK NRO, Inc. $768 27 payments
  7. Nevro Corp. $691 23 payments
  8. MML US, Inc. $510 6 payments
  9. Medtronic USA, Inc. $384 9 payments
  10. Vertiflex, Inc. $237 6 payments
  11. Other $1,515 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,161 227 payments
  2. Travel and Lodging $2,657 8 payments
  3. Consulting Fee $450 1 payment
Products named General payments · program years 2019–2025
  1. Evoke SCS $3,416 11 payments
  2. Vyrsa V1 $699 7 payments
  3. Prospera $597 23 payments
  4. OSTEOCOOL RF ABLATION SYSTEM $593 6 payments
  5. Proclaim Family of SCS IPGs $555 8 payments
  6. ReActiv8 $510 6 payments
  7. SlimTip lead DRG Lead $411 6 payments
  8. Senza $311 9 payments
  9. Evoke $305 7 payments
  10. OSTEOCOOL RF ABLATION $304 3 payments
  11. Other $5,196 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

960

Median for Anesthesiology: 322

Drug cost

$18,546

Median for Anesthesiology: $8,738

Branded share of claims

47.6%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 364 $10,289
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 53 $1,700
Gabapentin Generic 166 $1,481
Morphine Sulfate Generic 27 $1,407
Oxycodone Hcl Generic 49 $989
Morphine Sulfate Er Morphine Sulfate Brand 22 $639
Tramadol Hcl Generic 121 $604
Methadone Hcl Generic 15 $387
Diclofenac Sodium Generic 19 $352
Methylprednisolone Generic 38 $195

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$157,611

Of which drugs: $882

Medicare patients

475

Average age 75

Services billed

8,263

277 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Diabetes 28%
Depression 27%
Chronic kidney disease 22%
Osteoporosis 21%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 77 6,412 $644
Injection, methylprednisolone acetate, 40 mg J1030 Office 20 32 $151

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $139
$139 — —
Prolia
  • Amgen Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record